Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.60 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.54 |
| ▸ | CCR6 | P51684 | 3/20 | 0.53 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30284876 | 1.00 | GAA (0.60) | GAASMYD3CCR6CCNKCCNA2 | |
| SCHEMBL30284727 | 0.88 | CCR6 (0.71) | GAASMYD3CCR6CCNKCCNA2 | |
| SCHEMBL25079860 | 0.88 | CCR6 (0.71) | GAASMYD3CCR6CCNKCCNA2 | |
| SCHEMBL26461185 | 0.87 | SMYD3 (0.58) | GAASMYD3CCR6MAPT | |
| SCHEMBL30284834 | 0.82 | CCR6 (0.70) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25079815 | 0.82 | CCR6 (0.70) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25079573 | 0.82 | KIF11 (0.50) | GAASMYD3CDK2KIF11 | |
| SCHEMBL30284829 | 0.81 | CCR6 (0.71) | GAACCR6CCNKCCNA2CDK2 | |
| SCHEMBL25079843 | 0.81 | CCR6 (0.71) | GAACCR6CCNKCCNA2CDK2 | |
| SCHEMBL25079310 | 0.80 | CCR6 (0.61) | GAASMYD3CCR6CCNKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | GAA 506/4885SMYD3 2765/4885CCR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.